Small cells – big issues : biological implications and preclinical advancements in small cell lung cancer
(2024) In Molecular Cancer 23(1).- Abstract
Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative... (More)
Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.
(Less)
- author
- organization
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Molecular subtypes, Preclinical models, Small cell lung cancer, Translational progress
- in
- Molecular Cancer
- volume
- 23
- issue
- 1
- article number
- 41
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:38395864
- scopus:85185901886
- ISSN
- 1476-4598
- DOI
- 10.1186/s12943-024-01953-9
- language
- English
- LU publication?
- yes
- id
- 607a8f39-e29b-41d5-aeb5-a6a93ba9028a
- date added to LUP
- 2024-03-15 10:14:36
- date last changed
- 2024-04-12 04:36:36
@article{607a8f39-e29b-41d5-aeb5-a6a93ba9028a, abstract = {{<p>Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.</p>}}, author = {{Solta, Anna and Ernhofer, Büsra and Boettiger, Kristiina and Megyesfalvi, Zsolt and Heeke, Simon and Hoda, Mir Alireza and Lang, Christian and Aigner, Clemens and Hirsch, Fred R. and Schelch, Karin and Döme, Balazs}}, issn = {{1476-4598}}, keywords = {{Molecular subtypes; Preclinical models; Small cell lung cancer; Translational progress}}, language = {{eng}}, number = {{1}}, publisher = {{BioMed Central (BMC)}}, series = {{Molecular Cancer}}, title = {{Small cells – big issues : biological implications and preclinical advancements in small cell lung cancer}}, url = {{http://dx.doi.org/10.1186/s12943-024-01953-9}}, doi = {{10.1186/s12943-024-01953-9}}, volume = {{23}}, year = {{2024}}, }